Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
+0.70 (+0.42%)
Earnings Announcements

Janssen Shows Findings From Global, Multi-Center Trial Examining Amivantamab In Combination With Lazertinib In Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Published: 09/20/2020 12:59 GMT
Johnson & Johnson (JNJ) - Janssen Presents Findings From Global, Multi-center Trial Examining Amivantamab in Combination With Lazertinib in Patients With Egfr-mutated Non-small Cell Lung Cancer.
Revenue is expected to be $22.52 Billion
Adjusted EPS is expected to be $2.29

Next Quarter Revenue Guidance is expected to be $23.45 Billion
Next Quarter EPS Guidance is expected to be $2.40

More details on our Analysts Page.